The graph shows my base (the cash I have for investment) after all living expenses and is updated at month end. It reflects the deduction of advance rent set aside, typically 12-18 months, as well as any credit card debt. These deductions provide a more accurate representation of my true base after all living expenses. It does not, however, include capital gains tax I may owe, which will be deducted at the end of each year. My goals are to consistently grow this figure on an annual basis, maintain zero or near-zero debt, improve the consistency of my investing/trading habits and execution, and take full advantage of compounding over time.

This Weekly Update: December 5

Trades this week: Trimmed VLTLF for 100% gains in my ROTH account and bought TGTX with those funds.

News this week: FIP received approval to close on their acquisition of The Wheeling Corp, expanding their railroad. VLTLF produced their first lithium carbonate ahead of schedule. GLSI announces having enrolled 1,000 patients, the target, but will continue in the two cohorts of HLA types. This will increase their flexibility for multiple interim analysis. First MDNA11 data from MDNAF in the combo arm with Keytruda will come next week at ESMO. OCUL announced after hours by way of an 8-K filing that they will apply to the FDA a full year sooner than expected (more maybe) given the new FDA protocols and after confirming with the FDA.

Number of holdings: 9

Unrealized Gains/Losses today: DLO -6.53%; MDNAF +10.47%; FIP -5.73%; HROW +29.74%; OCUL +2.26%; VLTLF +193.68%; TGTX +0.29%; GOSS +23.92%; GLSI -21.48%

Next Update: December 12

On mobile devices the best view of the table below is likely horizontal orientation.

Ticker Company Reason I'm Buying
DLO DLocal Ltd. Long-term holder and have traded DLO twice this year profitably. DLocal is the undisputed in cross border payments, particularly in emerging markets. They're growing and have a long runway. TPV is popping, revenue is growing rapidly, EPS continues to rise. The take rate is declining as expected and profit margins with it. While typical for this type of company, the market doesn't know yet how to value DLO given these dynamics. I think if the EPS continues to rise and FCF as well (though unlikely in sync short-term) over the long-term as I expect, this will continue to be very attractive. DLocal is one of the lowest risk investments in the market, in my opinion. Solid management executing flawlessly and consistently. Integrations and major partnerships are announced on a rolling basis.
HROW Harrow Inc. New position, looking to be a long-term holder. Harrow is undervalued as an upcoming fastest growing ophthalmology company. They have the infrastructure, leadership, and execution to warrant a higher quarter over quarter growth rate than the market gives them credit for right now. A growth rate that should last for the next 6-8 quarters and beyond.
VLTLF LiberyStream Infrastructure Long-term holder. Previously Volt Lithium, LibertyStream is able to extract lithium from oil field brine, a waste product of oil drilling. This provides the opportunity for a second stream of income for oil companies and water treatment companies focused on extracting valuable resources from oilfield brine like LiberyStream's partner Wellspring Hydro. It also serves as a domestic supply of lithium for the US. The company has just recently completed the purchase of a small $2.5M chemistry set to convert their lithium chloride eluate to lithium carbonate, the finished product for the end user's requirements. We are waiting on JV announcement most likely with an oil company. The nearest competitor to VLTLF will require $1.5B and some years to construct their prototype whereas VLTLF is able to get going for just $50M and scale. JV announcement could be imminent.
MDNAF Medicenna Therapeutics Inc. Long-term holder and have traded profitably once before. Medicenna is in Phase 1/2 for their engineered IL2 in multiple cancer types both as a monotherapy and in combination with Keytruda. They have shown excellent monotherapy results, and the market has not yet seen combination data. It's been quiet for a bit, but the company just announced they will update with data on December 5 at an oncology conference. Will be very exciting to get this data. I believe this is an excellent candidate for large pharma to acquire. There are other drugs in the pipeline, but this is the one to watch.
FIP FTAI Infrastructure Reinitiated position at a lower price. Have sold FIP once for a loss and once for a gain this year. My conviction has changed now as the company continues to execute and is reaching several inflection points including the potential sale of Long Ridge possibly after or in conjunction with announcing more power off-take agreements, the construction of the Rapuano Storage Caverns, the integration their most recent acquisition which closed in August of the Wheeling & Lake Erie Railway Company basically doubling their rail business and financing options.
OCUL Ocular Therapeutix Inc. First trade recently initiated. Ocular is about to announce Phase 3 results in wet AMD. This is widely expected to be successful in the biotech investor community, and I believe the market will soon be forced to rerate and factor in the massive TAM and peak sales estimates between 3-5B. We could see a 100% move or more on this data and expectations for approval. The market is beginning to factor in and will start to give more value to the rest of their pipeline after late-stage trials begin for those (soon). Interestingly, the C-suite is also incentivized to get the stock over $30/sh. On 12/5/25, the Company filed an 8-K stating they will be filing in 2025 after the first Phase 3 is completed instead of waiting until the second Phase 3 completion in 2026 per new FDA protocols. Good news!
TGTX TG Therapeutics, Inc. Second trade for me. First was profitable, around 30% gain. The stock has since fallen near where I'd previously bought it at 27+, now 30+/share. Briumvi is FDA approved for adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). The relapse rate is something like once every 90 years. The sales growth has been steady and is expected to continue. Once patients are on Briumvi, they stay on so what is almost the equivalent of recurring revenue and profits here are massive in time. By 2030, likely looking at close to $2.5B annual sales. Current trials are for a modified dose regimen for easier administration in-clinic and a subcutaneous at-home administration trial, the latter of which is the most market expanding opportunity and data will be available on that sometime in 2027. The Company is profitable and there is little chance of further dilution.
GOSS Gossamer Bio Inc. First trade recently initiated. Phase 3 results in PAH expected February 2026. Massive upside potential. This is a catalyst play for me so position size adjusted down for that. Assuming it succeeds, I'll be looking to load more shares then.
GLSI Greenwich LifeSciences Long-term holder. Greenwich is in registrational Phase 3 for preventing breast cancer recurrence. Huge success in previous trial. 14 "events" needed to trigger the first interim analysis. Estimates from different AI tools put this somewhere between second half 2026 and second half 2027. I don't want to miss it. This could be a 1,000% gainer from here on positive results. CEO share purchases are consistent and high. A lot of skin in the game. On 12/5/2025, the Company announced they have enrolled 1,000 patients in either of the two HLA groups and will continue enrollment. There are multiple reasons why they cited. The adaptive protocol amendment, guided by the Steering Committee and emerging data on GP2 efficacy across HLA types, allows ongoing enrollment to generate more events for multiple interim analyses, refine cohort sizes, and support broader labeling claims (e.g., all HER2+ patients) while leveraging high screening rates (~150/quarter). This enhances regulatory flexibility and commercial potential without altering the primary endpoint power. The does not increase the time to interim analysis for which 14 "events" is required. An event here is defined as invasive breast cancer recurrence.